Danish central bank raises 2024 GDP forecast on Novo Nordisk, gas field restart
Reuters
Published Mar 20, 2024 20:48
COPENHAGEN (Reuters) - The Danish central bank on Wednesday almost doubled its forecast for economic growth this year due to strong production by drug maker Novo Nordisk (CSE:NOVOb) and the restart of natural gas production in the North Sea.
The central bank expects GDP to increase by 2.4% this year and 1.4% next year, up from a previous forecast of 1.3% for both years.
The higher growth projection was partly due to the increase in production abroad by Danish pharmaceutical companies and the restart this month of Denmark's Tyra gas field, which was shut for redevelopment in 2019, the central bank said.
"Without these two factors, we estimate that the Danish economy will grow at a more subdued rate of 0.8% this year," Governor Christian Kettel Thomsen said in a statement.
Novo Nordisk makes in-demand weight loss and diabetes drugs under the brand names Wegovy and Ozempic and the bank said its production abroad is included in Denmark's GDP even though many of the jobs are located outside the country.
The pharmaceutical giant's market valuation recently surpassed both Tesla (NASDAQ:TSLA) and Visa (NYSE:V), making it the world's 12th most valuable company.
Core inflation, which does not include the prices of energy and non-processed food, is expected to be 2.3% in 2024, 2.8% in 2025 and 2.0% in 2026, the central bank said.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.